Flavonoid derivatives as selective ABCC1 modulators: Synthesis and functional characterization

European Journal of Medicinal Chemistry

Volumn 109, Issue , 2016, Pages 124-133

  Obreque Balboa, José Esteban ^a   Sun, Qiu ^a   Bernhardt, Günther ^a   König, Burkhard ^a   Buschauer, Armin ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (BENZO[C][1,2,5]OXADIAZOL 5 YLMETHYL)PIPERAZIN 1 YL] 5,7 DIMETHOXY 4H CHROMEN 4 ONE; 5 HYDROXY 7 METHOXY 2 [4 (4 NITROBENZYL)PIPERAZINE 1 CARBONYL] 4H CHROMEN 4 ONE; 5 METHOXY 2 [4 (4 NITROBENZYL)PIPERAZIN 1 YL] 4H CHROMEN 4 ONE; 5,7 DIMETHOXY 2 (4 PHENETHYLPIPERAZIN 1 YL) 4H CHROMEN 4 ONE; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CYTOSTATIC AGENT; DOXORUBICIN; ETOPOSIDE; FLAVONOID; FUMITREMORGIN C; MULTIDRUG RESISTANCE PROTEIN 1; REVERSAN; TARIQUIDAR; UNCLASSIFIED DRUG; VERLUKAST; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER RESISTANCE; CARBON NUCLEAR MAGNETIC RESONANCE; CHEMOSENSITIVITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG STABILITY; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC50; KERATINOCYTE; MCF 7 CELL LINE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTON NUCLEAR MAGNETIC RESONANCE; AMINATION; ANIMAL; CELL LINE; CHEMISTRY; MCF-7 CELL LINE; METABOLISM; SYNTHESIS;

AMINATION; ANIMALS; CELL LINE; FLAVONOIDS; HUMANS; MCF-7 CELLS; MICE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PYRAZOLES; PYRIMIDINES;

EID: 84954156733     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2015.12.010     Document Type: Article

References (66)

1. M. Dean A. Rzhetsky R. Allikmets The human ATP-binding cassette (ABC) transporter superfamily Genome Res. 11 2001 1156 1166
2. H. Yabuuchi S.i. Takayanagi K. Yoshinaga N. Taniguchi H. Aburatani T. Ishikawa ABCC13, an unusual truncated ABC transporter, is highly expressed in fetal human liver, Biochem Biophys. Res. Commun. 299 2002 410 417
3. V. Vasiliou K. Vasiliou D. Nebert Human ATP-binding cassette (ABC) transporter family Hum. Genomics 3 2008 281 290
4. A.L. Davidson P.C. Maloney ABC transporters: how small machines do a big job Trends Microbiol. 15 2007 448 455
5. E.M. Leslie R.G. Deeley S.P.C. Cole Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense Toxicol. Appl. Pharmacol. 204 2005 216 237
6. R.G. Deeley C. Westlake S.P.C. Cole Transmembrane Transport of Endo- and Xenobiotics by Mammalian ATP-binding Cassette Multidrug Resistance Proteins 2006
7. G. Szakács A. Váradi C. Özvegy-Laczka B. Sarkadi The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox) Drug Discov. Today 13 2008 379 393
8. R.J. Kathawala P. Gupta C.R. Ashby Jr. Z.S. Chen The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade Drug Resist Updat 18 2015 1 17
9. M. Yu A. Ocana I.F. Tannock Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit? Cancer Metastasis Rev. 32 2013 211 227
10. Z. Binkhathlan A. Lavasanifar P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives Curr. Cancer Drug Targets 13 2013 326 346
11. M.M. Gottesman T. Fojo S.E. Bates Multidrug resistance in cancer: role of ATP-dependent transporters Nat. Rev. Cancer 2 2002 48 58
12. R.J. Ferreira D.J. dos Santos, M.J. Ferreira, P-glycoprotein and membrane roles in multidrug resistance Future Med. Chem. 7 2015 929 946
13. S. Cole G. Bhardwaj J. Gerlach J. Mackie C. Grant K. Almquist A. Stewart E. Kurz A. Duncan R. Deeley Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line Science 258 1992 1650 1654
14. S.P.C. Cole K.E. Sparks K. Fraser D.W. Loe C.E. Grant G.M. Wilson R.G. Deeley Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells Cancer Res. 54 1994 5902 5910
15. L.M. Breuninger S. Paul K. Gaughan T. Miki A. Chan S.A. Aaronson G.D. Kruh Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution Cancer Res. 55 1995 5342 5347
16. H.-K. Kang E. Lee H. Pyo S.-J. Lim Cyclooxygenase-independent down-regulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells Mol. Cancer Ther. 4 2005 1358 1363
17. M. Haber J. Smith S.B. Bordow C. Flemming S.L. Cohn W.B. London G.M. Marshall M.D. Norris Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma J. Clin. Oncol. 24 2006 1546 1553
18. M. Yoshioka H. Sagara F. Takahashi N. Harada K. Nishio A. Mori H. Ushio K. Shimizu T. Okada M. Ota Y.M. Ito O. Nagashima R. Atsuta T. Suzuki T. Fukuda Y. Fukuchi K. Takahashi Role of multidrug resistance-associated protein 1 in the pathogenesis of allergic airway inflammation, Am J. Physiol. Lung Cell Mol. Physiol. 296 2009 L30 L36
19. J. Weiss D. Theile N. Ketabi-Kiyanvash H. Lindenmaier W.E. Haefeli Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by Nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors Drug Metab. Disposition 35 2007 340 344
20. J. Martin-Broto A.M. Gutierrez R.F. Ramos J.A. Lopez-Guerrero S. Ferrari S. Stacchiotti P. Picci S. Calabuig P. Collini M. Gambarotti S. Bague A.P. Dei Tos E. Palassini P. Luna J. Cruz R. Cubedo J. Martinez-Trufero A. Poveda P.G. Casali A. Fernandez-Serra A. Lopez-Pousa A. Gronchi MRP1 overexpression determines poor prognosis in prospectively treated patients with localized high-risk soft tissue sarcoma of limbs and trunk Wall: an ISG/GEIS study Mol. Cancer Ther. 13 2014 249 259
21. S.P.C. Cole Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future Annu. Rev. Pharmacool. Toxicol. 54 2014 95 117
22. D. Trompier H. Baubichon-Cortay X.B. Chang M. Maitrejean D. Barron J.R. Riordan A. Di Pietro Multiple flavonoid-binding sites within multidrug resistance protein MRP1 Cell. Mol. Life Sci. 60 2003 2164 2177
23. H. Nguyen S. Zhang M.E. Morris Effect of flavonoids on MRP1-mediated transport in Panc-1 cells J. Pharm. Sci. 92 2003 250 257
24. S.-F. Zhou L.-L. Wang Y.M. Di C.C. Xue W. Duan C.G. Li Y. Li Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development Curr. Med. Chem. 15 2008 1981 2039
25. C.A. Burkhart F. Watt J. Murray M. Pajic A. Prokvolit C. Xue C. Flemming J. Smith A. Purmal N. Isachenko P.G. Komarov K.V. Gurova A.C. Sartorelli G.M. Marshall M.D. Norris A.V. Gudkov M. Haber Small-Molecule multidrug Resistance-Associated protein 1 inhibitor reversan increases the therapeutic Index of chemotherapy in mouse models of neuroblastoma Cancer Res. 69 2009 6573 6580
26. N. Tawari S. Bag M. Degani Pharmacophore mapping of a series of pyrrolopyrimidines, indolopyrimidines and their congeners as multidrug-resistance-associated protein (MRP1) modulators J. Mol. Model. 14 2008 911 921
27. R. Kanin S. Sergio Mares P. Jeffrey Virtual screening of ABCC1 transporter nucleotidebinding domains as a therapeutic target in multidrug resistant cancer Bioinformation 8 2012
28. I.L.K. Wong K.-F. Chan K.H. Tsang C.Y. Lam Y. Zhao T.H. Chan L.M.C. Chow Modulation of multidrug resistance protein 1 (MRP1/ABCC1)-Mediated multidrug resistance by bivalent apigenin homodimers and their derivatives J. Med. Chem. 52 2009 5311 5322
29. C. Ochoa-Puentes P. Höcherl M. Kühnle S. Bauer K. Bürger G. Bernhardt A. Buschauer B. König Solid phase synthesis of tariquidar-related modulators of ABC transporters preferring breast cancer resistance protein (ABCG2) Bioorg. Med. Chem. Lett. 21 2011 3654 3657
30. M. Egger X. Li C. Müller G. Bernhardt A. Buschauer B. König Tariquidar analogues: synthesis by CuI-catalysed N/O-Aryl coupling and inhibitory activity against the ABCB1 transporter Eur. J. Org. Chem. 2007 2007 2643 2649
31. M. Kühnle M. Egger C. Müller A. Mahringer G. Bernhardt G. Fricker B. König A. Buschauer Potent and selective inhibitors of breast Cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar J. Med. Chem. 52 2009 1190 1197
32. C. Ochoa-Puentes S. Bauer M. Kühnle G. Bernhardt A. Buschauer B. König Benzanilide-Biphenyl replacement: a bioisosteric approach to Quinoline carboxamide-type ABCG2 modulators ACS Med. Chem. Lett. 4 2013 393 396
33. S. Bauer C. Ochoa-Puentes Q. Sun M. Bause G. Bernhardt B. König A. Buschauer Quinoline carboxamide-type ABCG2 Modulators: Indole and Quinoline moieties as anilide replacements ChemMedChem 8 2013 1773 1778
34. G.D. Hatnapure A.P. Keche A.H. Rodge S.S. Birajdar R.H. Tale V.M. Kamble Synthesis and biological evaluation of novel piperazine derivatives of flavone as potent anti-inflammatory and antimicrobial agent Bioorg. Med. Chem. Lett. 22 2012 6385 6390
35. C.A. Merlic S. Motamed B. Quinn Structure determination and synthesis of fluoro nissl Green: an RNA-binding fluorochrome J. Org. Chem. 60 1995 3365 3369
36. A.H. Li C.H. Chiu H.W. Chang W.C. Chang W. Li Phase evolution and magnetic properties of PrxFe82g'xg'yTiyCo10B4C4 (x Combining double low line 9-10.5; y Combining double low line 0, 2) nanocomposites J. Alloys Compd. 437 2007 197 202
37. G. Valdameri E. Genoux-Bastide B. Peres C. Gauthier J. Guitton R. Terreux S.M.B. Winnischofer M.E.M. Rocha A. Boumendjel A. Di Pietro Substituted chromones as highly potent nontoxic inhibitors, specific for the breast Cancer resistance protein J. Med. Chem. 55 2012 966 970
38. M. Funke D. Thimm A.C. Schiedel C.E. Müller 8-Benzamidochromen-4-one-2-carboxylic acids: potent and selective agonists for the Orphan g protein-coupled receptor GPR35 J. Med. Chem. 56 2013 5182 5197
39. R. Knorr A. Trzeciak W. Bannwarth D. Gillessen New coupling reagents in peptide chemistry Tetrahedron Lett. 30 1989 1927 1930
40. S. Bauer Quinoline Carboxamides as Modulators of Breast Cancer Resistance Protein (ABCG2): Investigations on Potency, Selectivity, Mechanism of Action, Cytotoxicity, Stability and Drug-like properties., in 2014 University of Regensburg
41. M. Kühnle Experimental Therapy and Detection of Glioblastoma: Investigation of Nanoparticles, ABCG2 Modulators and Optical Imaging of Intracerebral Xenografts, in 2010 University of Regensburg
42. S.N. Moreno R. Docampo Mechanism of toxicity of nitro compounds used in the chemotherapy of trichomoniasis Environ. Health Perspect. 64 1985 199 208
43. P. Boukamp R.T. Petrussevska D. Breitkreutz J. Hornung A. Markham N.E. Fusenig Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line J. Cell Biol. 106 1988 761 771
44. A.S. Mehanna J.Y. Kim Design, synthesis, and biological testing of thiosalicylamides as a novel class of calcium channel blockers Biorg. Med. Chem. 13 2005 4323 4331
45. M. Koufaki C. Kiziridi P. Papazafiri A. Vassilopoulos A. Varro Z. Nagy A. Farkas A. Makriyannis Synthesis and biological evaluation of benzopyran analogues bearing class III antiarrhythmic pharmacophores Biorg. Med. Chem. 14 2006 6666 6678
46. K.S. Putt G.W. Chen J.M. Pearson J.S. Sandhorst M.S. Hoagland J.T. Kwon S.K. Hwang H. Jin M.I. Churchwell M.H. Cho D.R. Doerge W.G. Helferich P.J. Hergenrother Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy Nat. Chem. Biol. 2 2006 543 550
47. M. Perez M. Lamothe C. Maraval E. Mirabel C. Loubat B. Planty C. Horn J. Michaux S. Marrot R. Letienne C. Pignier A. Bocquet F. Nadal-Wollbold D. Cussac L. de Vries B. Le Grand Discovery of novel protease activated receptors 1 antagonists with potent antithrombotic activity in vivo J. Med. Chem. 52 2009 5826 5836
48. K. Kumar D. Michalik I.G. Castro A. Tillack A. Zapf M. Arlt T. Heinrich H. Bottcher M. Beller Biologically active compounds through catalysis: efficient synthesis of N-(heteroarylcarbonyl)-N '-(arylalkyl)piperazines Chem-Eur J. 10 2004 746 757
49. Q.P. Peterson D.C. Hsu D.R. Goode C.J. Novotny R.K. Totten P.J. Hergenrother Procaspase-3 activation as an Anti-Cancer strategy: structure-activity relationship of procaspase-activating compound 1 (PAC-1) and its cellular co-localization with Caspase-3 J. Med. Chem. 52 2009 5721 5731
50. E.C.W. Witte, Hans Peter; Hagenbruch, Bernd; Stegmeier, Karlheinz; Pill, Johannes, carboxylic acid derivatives and drugs containing them, in, Boehringer Mannh. G.m.b.H., Fed. Rep. Ger.., 1983, pp. 97.
51. T. Liu Z. Weng X. Dong L. Chen L. Ma S. Cen N. Zhou Y. Hu Design, synthesis and biological evaluation of novel piperazine derivatives as CCR5 antagonists PLoS One 8 2013 e53636
52. Z. Omran T. Cailly E. Lescot J.S.D. Santos J.H. Agondanou V. Lisowski F. Fabis A.M. Godard S. Stiebing G. Le Flem M. Boulouard F. Dauphin P. Dallemagne S. Rault Synthesis and biological evaluation as AChE inhibitors of new indanones and thiaindanones related to donepezil Eur. J. Med. Chem. 40 2005 1222 1245
53. M.X. Dong L. Lu H.T. Li X.H. Wang H. Lu S.B. Jiang Q.Y. Dai Design, synthesis, and biological activity of novel 1,4-disubstituted piperidine/piperazine derivatives as CCR5 antagonist-based HIV-1 entry inhibitors Bioorg. Med. Chem. Lett. 22 2012 3284 3286
54. S.X. Huang B. Cao C. Morisseau Y. Tin B.D. Hammock Y.Q. Long Structure-based optimization of the piperazino-containing 1,3-disubstituted ureas affording sub-nanomolar inhibitors of soluble epoxide hydrolase Medchemcomm 3 2012 379 384
55. J.J.C. Baldwin A. David Jason M. Elliott Gerald S. Ponticello David C. Remy Harold G. Selnick Preparation and Formulation of Benzofurazan Derivatives as Antiarrhythmics 1991 Merck and Co., Inc. USA 28
56. D.A. Thorat M.R. Doddareddy S.H. Seo T.-J. Hong Y.S. Cho J.-S. Hahn A.N. Pae Synthesis and biological evaluation of 2,4-diaminoquinazoline derivatives as novel heat shock protein 90 inhibitors Bioorg. Med. Chem. Lett. 21 2011 1593 1597
57. Y. Chai L. Wang H. Sun C. Guo Y. Pan Gas-Phase chemistry of benzyl cations in dissociation of n-benzylammonium and n-benzyliminium ions studied by mass spectrometry J. Am. Soc. Mass. Spectrom. 23 2012 823 833
58. J.H. Yu Y.S. Yang R.Y. Ji A mild and efficient procedure for the preparation of chromone-2-carboxylates Chin. Chem. Lett. 17 2006 1005 1008
59. M. Hadjeri M. Barbier X. Ronot A.-M. Mariotte A. Boumendjel J. Boutonnat Modulation of p-glycoprotein-mediated multidrug resistance by flavonoid derivatives and analogues J. Med. Chem. 46 2003 2125 2131
60. M.I. Fernández-Bachiller C. Pérez L. Monjas J. Rademann M.I. Rodríguez-Franco New Tacrine-4-oxo-4 h -chromene hybrids as Multifunctional agents for the treatment of Alzheimer's disease, with cholinergic, antioxidant, and β-amyloid-reducing properties J. Med. Chem. 55 2012 1303 1317
61. T.K. Yasuma, Masahiro; Mori, Akira, Preparation of chromone derivatives as osteogenesis promoters and process for the preparation of the same, in, Takeda chemical Industries, Ltd., Japan, 2001, pp. 64.
62. N. Dodic B. Dumaitre A. Daugan P. Pianetti Synthesis and activity against multidrug resistance in chinese hamster Ovary cells of new acridone-4-carboxamides J. Med. Chem. 38 1995 2418 2426
63. M. Roe A. Folkes P. Ashworth J. Brumwell L. Chima S. Hunjan I. Pretswell W. Dangerfield H. Ryder P. Charlton Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives Bioorg. Med. Chem. Lett. 9 1999 595 600
64. M. Hubensack C. Müller P. Höcherl S. Fellner T. Spruss G. Bernhardt A. Buschauer Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice J. Cancer Res. Clin. Oncol. 134 2008 597 607
65. É. Bakos R. Evers G. Szakács G.E. Tusnády E. Welker K. Szabó M. de Haas L. van Deemter P. Borst A. Váradi B. Sarkadi Functional multidrug resistance protein (MRP1) lacking the n-terminal transmembrane domain J. Biol. Chem. 273 1998 32167 32175
66. G. Bernhardt H. Reile H. Birnböck T. Spruß H. Schönenberger Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity J. Cancer Res. Clin. Oncol. 118 1992 35 43